



IFW

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/528,208
	Filing Date	March 17, 2005
	First Named Inventor	Meier
	Art Unit	1645
	Examiner Name	Unknown
Total Number of Pages in This Submission	Attorney Docket Number	606-42-PCT-PA

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<b>Remarks</b> Please apply any deficiencies or overpayments to deposit account 502362.	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Gabor L. Szekeres
Signature	<i>Gabor L. Szekeres</i>
Date	December 22, 2005

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.	
Typed or printed name	Toni Whyte
Signature	<i>Toni Whyte</i>
Date	December 22, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



ATTORNEY DOCKET NO. 606-42-PCT-PA

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of ) Examiner: Unknown  
Meier, et al. ) Art Unit: 1645  
Serial No.: 10/528,208 )  
Filed: March 17, 2005 )  
For: Antibody and Screening Method )

INFORMATION DISCLOSURE  
STATEMENT

Mail Stop DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Certificate of Mailing

I hereby certify that this correspondence is being deposited on December 22, 2005 with the United States Postal Service First Class Mail addressed to: Mail Stop DD, Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

Toni Whyte  
Toni Whyte  
December 22, 2005  
Date

Dear Sir:

Pursuant to 37 CFR Sections 1.97 and 1.98, and in fulfillment of the duty of candor set forth in 37 CFR Section 1.56, Applicant cites the following documents listed on Form 1449, submitted herewith. Copies of the non-US patent references are enclosed.

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code² (if known)			
		US-6,140,075			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T³
		Country Code -Number-Kind² (if known)				
		WO 94/13804				
		WO 0183806 A1				
		WO 0005391 A1				

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		Belanger H, Fleysh N, Cox S, Bartman G, Deka D, Trudel M, Koprowski H, Yusibov V. Human respiratory syncytial virus vaccine antigen produced in plants. FASEB J. 2000 Nov; 14(14):2323-2328.
		Bouquin T, Thomsen M, Nielsen LK, Green TH, Mundy J and Dziegiel MH (2002) Human anti-Rhesus D IgG1 antibody produced in transgenic plants. Transgenic Res 11: 115-122.
		Chargelegue D, Vine ND, van Dolleweerd CJ, Drake PM, Ma JK. A murine monoclonal antibody produced in transgenic Res. 2000 Jun; 9(3):187-94
		De Jaeger G, De Wilde C, Eeckhout D, Fiers D, Depicker A. The plantibody approach: expression of antibody genes in plants to modulate plant metabolism or to obtain pathogen resistance, Plant Mol Biol. 2000 Jul; 43 (4):419-28.
		Fischer R and Emans N (2000) Molecular farming of pharmaceutical proteins. Transgenic Res 9: 279-299.
		Giddings G, Allison G, Brooks D and Carter A (2000) Transgenic plants as factories for biopharmaceuticals. Nat Biotechnol 18: 1151-1155.
		Isaacs JD. The antiglobulin response to therapeutic antibodies. Seminars in Immunology 1990; 2: 449-456.
		Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497.
		Ma JK, Hikmat BY, Wycoff K, Vine ND, Chargelegue D, Yu L et al. (1998) Characterization of a recombinant plant monoclonal secretory antibody of preventive immunotherapy in humans Nat Med 4:601-606.
		Richter LJ, Thanavala Y, Arntzen CJ, Mason HS. Production of hepatitis B surface antigen in transgenic plants for oral immunization. Nat Biotechnol. 2000 Nov; 18 (11): 1167-1171.
		Verch T, Yusibov V and Koprowski H (1998) Expression and assembly of a full length monoclonal antibody in plants using a plant virus vector. J Immunol Methods 220: 69-75.
		Zeitlin L, Olmsted SS, Moench TR, Col MS, Martinell BJ, Paradkar VM et al. (1998) A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes. Nat Biotechnol 16: 1361-1364.
		Hiatt A, Cafferkey R and Bowdish K (1989) Production of antibodies in transgenic plants. Nature 342:76-78
		Will, et al., 1996.
		Power et al., 1995.
		Regnault et al., (1999) J exp Med. 189: 371-380.
		Ward, E.S. et al., Nature 341:544-546 (1989).

		Bird et al., Science 242: 423-426 (1988)	
		Huston et al., PNAS USA 85: 5879-5883 (1988)	
		P. Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993).	
		Velten et al., 1984	
		Shen and Forde (1989)	
		Bechtold and Pelletier, 1998	
		Clough and Bent, 1998	
		BIOSIS, accession no. PREV200200359263, Bouquin Thomas et al, " human anti-Rhesus D IgG1 antibody produced in transgenic plants" Transgenic Research, (2002), vol. 11, no.2, pg115-122, page 116-117	
		Eur J Immunol. Vol. 24, no.1, 1994 Jan, Ma JK, Lehner T. et al: "Assembly of monoclonal antibodies with IgA heavy chain domains in transgenic tobacco plants" pages 131-138, page 132, section 2,4	
		Plant J. volume 27, no. 3, 2001 Aug. Li X, Song Y et al, "A fast neutron deletion mutagenesis-based reverse genetics system for plants," pgs 235-242, page 237	
		BIOSIS, accession no. PREV 19990087821, McCormick Alison A et al, "Rapid production of specific vaccines for lymphoma by expression of the tumor derived single-chain Fv Epitopes in tobacco plants," Proceedings of the National Academy of Sciences of the United States of America, (1999), vol. 96, No. 2, pg 703-7608, page 703, right column	
		Biosis, accession no. PREV 199900255881, Franconi Rosella et al, "Functional expression in bacteria and plants of an scFv antibody fragment against tospoviruses," Immunotechnology (Shannon), (1999), vol.4, no. 3-4, pg 189-201, abstract	
		In Vitro Cellular and Development biology animal, volume 38, 2002, Yong-Quiang et al: "Produce and Characterize Several Classes of Plantibodies (Plant made Monoclonal Antibodies," page 1141, page 56-A, abstract	<input type="checkbox"/>
		Molecular Biotechnology, vol. 20, 2002, GG Zhang et al, "Production of HIV-1 p24 protein in transgenic tobacco plants," 131-136.	<input type="checkbox"/>
		Vaccine, vol 19, 2001, SJ Streatfield et al, "Plant based vaccines: unique advantages," 2742-2748.	<input type="checkbox"/>
		Proc. Natl. Acad. Sci. USA, vol 98, 2001, R Mahalingam & N Fedoroff, "Screening insertion libraries for mutations in any genes simultaneously using DNA microarrays," 7420-7425.	<input type="checkbox"/>
		<a href="http://www.arabidopsis.org/abrc/scheible.html">http://www.arabidopsis.org/abrc/scheible.html</a> , "T-DNA transformed activation tag lines from W Scheible and C Somerville" last modified 29.08. 2001.	<input type="checkbox"/>


REMARKS

Submission of the foregoing document is no representation that a search was made, or if made, that it was comprehensive, or that no other documents exist which may be material to the above-identified application. Moreover, the Applicant does not concede that the foregoing documents are necessarily prior art to the invention. In the event a fee is required, the Commissioner is hereby authorized to charge deposit account number 502362. A copy of this page for that purpose is enclosed.

Date: Dec 22, 2005

By: Gabor L. Szekeres  
Gabor L. Szekeres  
Registration No. 28,675

Law Offices of Gabor L. Szekeres  
8141 E. Kaiser Boulevard, Ste. 112  
Anaheim, CA 92808  
Telephone: (714) 998-3295 Facsimile: (714) 998-3296



Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

Sheet	1	of	5
-------	---	----	---

**Complete if Known**

<b>Application Number</b>	<b>10/528,208</b>
<b>Filing Date</b>	<b>March 17, 2005</b>
<b>First Named Inventor</b>	<b>Meier, et al.</b>
<b>Art Unit</b>	<b>1645</b>
<b>Examiner Name</b>	<b>Unknown</b>
<b>Attorney Docket Number</b>	<b>606-42-PCT-PA</b>

U.S. PATENT DOCUMENTS[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner  
Signature**

Date  
Considered

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>2</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES FOR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT***(use as many sheets as necessary)*

Sheet

2

5

**Complete if Known**

Applicant Number	10/528,208
Filing Date	March 17, 2005
First Named Inventor	Meier, et al.
Group Art Unit	1645
Examiner Name	Unknown
Attorney Docket Number	606-42-PCT-PA

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		Belanger H, Fleysch N, Cox S, Bartman G, Deka D, Trudel M, Koprowski H, Yusibov V. Human respiratory syncytial virus vaccine antigen produced in plants. FASEB J. 2000 Nov; 14(14):2323-2328.	<input type="checkbox"/>
		Bouquin T, Thomsen M, Nielsen LK, Green TH, Mundy J and Dziegiel MH (2002) Human anti-Rhesus D IgG1 antibody produced in transgenic plants. Transgenic Res 11: 115-122.	<input type="checkbox"/>
		Chargelegue D, Vine ND, van Dolleweerd CJ, Drake PM, Ma JK. A murine monoclonal antibody produced in transgenic Res. 2000 Jun; 9(3):187-94	<input type="checkbox"/>
		De Jaeger G, De Wilde C, Eeckhout D, Fiers D, Depicker A. The plantibody approach: expression of antibody genes in plants to modulate plant metabolism or to obtain pathogen resistance. Plant Mol Biol. 2000 Jul; 43 (4):419-28.	<input type="checkbox"/>
		Fischer R and Emans N (2000) Molecular farming of pharmaceutical proteins. Transgenic Res 9: 279-299.	<input type="checkbox"/>
		Giddings G, Allison G, Brooks D and Carter A (2000) Transgenic plants as factories for biopharmaceuticals. Nat Biotechnol 18: 1151-1155.	<input type="checkbox"/>
		Isaacs JD. The antiglobulin response to therapeutic antibodies. Seminars in Immunology 1990; 2: 449-456.	<input type="checkbox"/>
		Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497.	<input type="checkbox"/>
		Ma JK, Hikmat BY, Wycoff K, Vine ND, Chargelegue D, Yu L et al. (1998) Characterization of a recombinant plant monoclonal secretory antibody of preventive immunotherapy in humans Nat Med 4:601-606.	<input type="checkbox"/>

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 5

## Complete if Known

Applicant Number	10/528,208
Filing Date	March 17, 2005
First Named Inventor	Meier, et al.
Group Art Unit	1645
Examiner Name	Unknown
Attorney Docket Number	606-42-PCT-PA

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		Richter LJ, Thanavala Y, Arntzen CJ, Mason HS. Production of hepatitis B surface antigen in transgenic plants for oral immunization. Nat Biotechnol. 2000 Nov; 18 (11): 1167-1171.	<input type="checkbox"/>
		Verch T, Yusibov V and Koprowski H (1998) Expression and assembly of a full length monoclonal antibody in plants using a plant virus vector. J Immunol Methods 220: 69-75.	<input type="checkbox"/>
		Zeitlin L, Olmsted SS, Moench TR, Col MS, Martinell BJ, Paradkar VM et al. (1998) A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes. Nat Biotechnol 16: 1361-1364.	<input type="checkbox"/>
		Hiatt A, Cafferkey R and Bowdish K (1989) Production of antibodies in transgenic plants. Nature 342:76-78	<input type="checkbox"/>
		Will, et al., 1996.	<input type="checkbox"/>
		Power et al., 1995.	<input type="checkbox"/>
		Regnault et al., (1999) J exp Med. 189: 371-380	<input type="checkbox"/>
		Ward, E.S. et al., Nature 341:544-546 (1989).	<input type="checkbox"/>
		Bird et al., Science 242: 423-426 (1988)	<input type="checkbox"/>
		Huston et al., PNAS USA 85: 5879-5883 (1988)	<input type="checkbox"/>

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 5

## **Complete if Known**

Applicant Number	10/528,208
Filing Date	March 17, 2005
First Named Inventor	Meier, et al.
Group Art Unit	1645
Examiner Name	Unknown
Attorney Docket Number	606-42-PCT-PA

## **OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		P. Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993).	<input type="checkbox"/>
		Velten et al., 1984	<input type="checkbox"/>
		Shen and Forde (1989)	<input type="checkbox"/>
		Bechtold and Pelletier, 1998	<input type="checkbox"/>
		Clough and Bent, 1998	<input type="checkbox"/>
		BIOSIS, accession no. PREV200200359263, Bouquin Thomas et al, " human anti-Rhesus D igG1 antibody produced in transgenic plants" Transgenic Research, (2002), vol. 11, no.2, pg115-122, page 116-117	<input type="checkbox"/>
		Eur J Immunol. Vol. 24, no.1, 1994 Jan, Ma JK, Lehner T. et al: "Assembly of monoclonal antibodies with IgA heavy chain domains in transgenic tobacco plants" pages 131-138, page 132, section 2,4	<input type="checkbox"/>
		Plant J. volume 27, no. 3, 2001 Aug. Li X, Song Y et al, "A fast neutron deletion mutagenesis-based reverse genetics system for plants," pgs 235-242, page 237	<input type="checkbox"/>
		BIOSIS, accession no. PREV 19990087821, McCormick Alison A et al, "Rapid production of specific vaccines for lymphoma by expression of the tumor derived single-chain Fv Epitopes in tobacco plants," Proceedings of the National Academy of Sciences of the United States of America, (1999), vol. 96, No. 2, pg 703-7608, page 703, right column	<input type="checkbox"/>
		Biosis, accession no. PREV 199900255881, Franconi Rosella et al, "Functional expression in bacteria and plants of an scFv antibody fragment against tospoviruses," Immunotechnology (Shannon), (1999), vol.4, no. 3-4, pg 189-201, abstract	<input type="checkbox"/>

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

*(use as many sheets as necessary)*

5

Q:

5

A.

606-42-PCT-PA

[illegible]

Considered

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231